- Coordinator
- Universiteit Twente, Netherlands
- Runs
- 1 June 2022 to 30 November 2023
- Status
- Finished
- EU funding
- €150k
- Total cost
- —
- Partners
- 1 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101069263
What the project is doing
In the project's own words, from its summary on CORDIS.
Needle-based injections are very common in modern medicine, notably in ongoing vaccination efforts worldwide. However, needle phobia and infection risks affect patient compliance with medical treatments, while millions of used needles contaminate the environment. Lastly, the effectiveness of certain drugs increases when injected intradermally, but targeting the dermis is challenging. Thus, new minimal-invasive procedures are needed.
Jet injectors are needle-free medical devices that pressurize thin liquid filaments to penetrate the skin. Jet injections have been effective in subcutaneous and intramuscular delivery, ex vivo, and in vivo. However, the expected needle-free revolution for medical treatments has neither been fulfilled, nor widely commercialized due to factors such as: a) Bruising, a painful consequence of delivering large volumes in a single location. b) When using wrong energy settings, or misalignment with respect to the skin, the injected liquid can perfuse other layers. c) The rejected liquid splashes back, leading to an incorrect dose delivery, risks of cross contamination of the injector parts, or splash-back on the care giver. d) Commercial jet injection methods, such as springs or compressed gas, are noisy which can distress the patient.
Hence, there is a need to develop a new way to deliver smaller doses with maximum accuracy in targeting specific skin layers. Bold-Jet is aimed at revolutionizing the experience of people who receive or perform frequent injections by developing for the first time a needle-free device using microjets that is safer, minimally invasive, and eco-friendly. By avoiding the use of needles, we can increase adherence to treatments by patients with fear to sharps and expand clinical routes for existing drugs and treatment.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Universiteit Twente | Enschede | Netherlands | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI